BIOVAIL/VALEANT
Biovail Corp., Canada’s largest pharmaceutical company, already had several things in common with California-based Valeant Pharmaceuticals International before the two announced a $3.2 billion merger on June 21. Their shared areas of focus include specialty central nervous system drugs, dermatology products, the Canadian market, and emerging markets. Biovail shareholders will own 50.5 percent of the new company, which will be based in the Toronto suburb of Mississauga.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
